Cargando…
Preclinical efficacy and toxicity studies of a highly specific chimeric anti‐CD47 antibody
Cluster of differentiation 47 (CD47) is a widely expressed self‐protection transmembrane protein that functions as a critical negative regulator to induce macrophage‐mediated phagocytosis. Overexpression of CD47 enables cancer cells to escape immune surveillance and destruction by phagocytes both in...
Autores principales: | Xu, Zhiqiang, Gao, Jing, Yao, Jingyun, Yang, Teddy, Wang, Dongxu, Dai, Chaohui, Ding, Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931223/ https://www.ncbi.nlm.nih.gov/pubmed/33449453 http://dx.doi.org/10.1002/2211-5463.13084 |
Ejemplares similares
-
Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential
por: Ma, Linlin, et al.
Publicado: (2020) -
Development and characterization of a novel human CD137 agonistic antibody with anti‐tumor activity and a good safety profile in non‐human primates
por: Gao, Yingying, et al.
Publicado: (2022) -
Anti-CD47 antibody eliminates bone tumors in rats
por: Fang, Shiqiang, et al.
Publicado: (2019) -
Anti-CD47 Antibody Enhances the Efficacy of Chemotherapy in Patients with Gastric Cancer Liver Metastasis
por: Liu, Zhaorui, et al.
Publicado: (2023) -
Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies
por: Pietsch, E C, et al.
Publicado: (2017)